# Bronchiolitis Obliterans Syndrome Following High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Neuroblastoma

**Authors:** Naomi Ogawa, Daisuke Morita, Hirokazu Morokawa, Kazutoshi Komori, Kazuo Sakashita

PMC · DOI: 10.7759/cureus.102291 · Cureus · 2026-01-26

## TL;DR

A child with neuroblastoma developed bronchiolitis obliterans syndrome after high-dose chemotherapy and autologous stem cell transplant, but showed improvement with treatment.

## Contribution

This case report highlights the rare occurrence of BOS after auto-HSCT and suggests it may be reversible in children.

## Key findings

- BOS occurred after auto-HSCT in a pediatric neuroblastoma patient.
- Multimodal therapy led to symptom resolution despite persistent radiographic changes.
- BOS after auto-HSCT may have a more reversible course compared to allo-HSCT.

## Abstract

Bronchiolitis obliterans syndrome (BOS) is a chronic obstructive pulmonary disorder most often recognized as a pulmonary manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT). Its occurrence following autologous HSCT (auto-HSCT) is exceedingly rare, and its clinical features and prognosis remain poorly defined. We report the case of a five-year-old girl with neuroblastoma who developed BOS after high-dose chemotherapy with thiotepa and melphalan followed by auto-HSCT. Respiratory symptoms, including dyspnea, wheeze, and oxygen desaturation, emerged almost simultaneously with hematopoietic engraftment. Computed tomography demonstrated mosaic attenuation with air trapping, and pulmonary function tests revealed peripheral airway obstruction, while infectious evaluations were entirely negative. Despite initial treatment with bronchodilators and corticosteroids, symptoms persisted beyond six weeks, leading to a diagnosis of BOS. Multimodal therapy, including methylprednisolone pulse therapy, intravenous immunoglobulin, inhaled corticosteroids, and azithromycin, resulted in the resolution of clinical symptoms and discontinuation of oxygen supplementation, although radiographic abnormalities remained. This case suggests that, although BOS is generally considered irreversible after allo-HSCT, BOS following auto-HSCT in children may follow a more reversible course, underscoring the importance of timely diagnosis and therapeutic intervention, and supporting the concept that the underlying mechanisms of BOS may differ between allo- and auto-HSCT.

## Linked entities

- **Chemicals:** thiotepa (PubChem CID 5453), melphalan (PubChem CID 460612), methylprednisolone (PubChem CID 6741), azithromycin (PubChem CID 447043)
- **Diseases:** neuroblastoma (MONDO:0005072), bronchiolitis obliterans syndrome (MONDO:0015265), chronic graft-versus-host disease (MONDO:0020547)

## Full-text entities

- **Genes:** MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, SFTPD (surfactant protein D) [NCBI Gene 6441] {aka COLEC7, PSP-D, SFTP4, SP-D}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** adrenal tumor (MESH:D000310), asthma (MESH:D001249), GVHD (MESH:D006086), multiple myeloma (MESH:D009101), dyspnea (MESH:D004417), Respiratory complications (MESH:D012140), fibrosis (MESH:D005355), small-airway dysfunction (MESH:D056151), airway inflammation (MESH:D007249), oxygen desaturation (MESH:D000860), Neuroblastoma (MESH:D009447), airway injury (MESH:D000402), pneumonia (MESH:D011014), airflow obstruction (MESH:D029424), organ injury (MESH:D009102), BOS (MESH:D000092122), cytomegalovirus (MESH:D003586), air trapping (MESH:C536657), radiographic abnormalities (MESH:D000089202), bronchiolitis obliterans (MESH:D001989), cough (MESH:D003371), capillary leak syndrome (MESH:D019559), cytotoxic (MESH:D064420), Chlamydia pneumoniae (MESH:D023521), infection (MESH:D007239), obstructive impairment (MESH:D001157), epithelial injury (MESH:D009375), anemia (MESH:D000740), Bordetella pertussis (MESH:D014917), acute bronchiolitis (MESH:D001988), immune dysregulation (OMIM:614878), tuberculosis (MESH:D014376), interstitial pneumonia (MESH:D017563), congestive heart failure (MESH:D006333), wheeze (MESH:D012135), abdominal distension (MESH:D000007), lymphoma (MESH:D008223)
- **Chemicals:** pirarubicin (MESH:C027260), oxygen (MESH:D010100), azithromycin (MESH:D017963), cyclophosphamide (MESH:D003520), thiotepa (MESH:D013852), TEPA (MESH:D013721), imatinib (MESH:D000068877), Methylprednisolone (MESH:D008775), etoposide (MESH:D005047), BU (MESH:D002066), carboplatin (MESH:D016190), montelukast (MESH:C093875), prednisolone (MESH:D011239), beta2-agonists (-), melphalan (MESH:D008558), cisplatin (MESH:D002945), ICE (MESH:D007053), ifosfamide (MESH:D007069)
- **Species:** Mycoplasmoides pneumoniae (Filterable agent of primary atypical pneumonia, species) [taxon 2104], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936193/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936193/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936193/full.md

---
Source: https://tomesphere.com/paper/PMC12936193